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I
n a creative retrospective cohort study, Jin and colleagues evaluated 99,549 women who received co-testing with cytology and HPV for primary cervical cancer screening during a 3-year screening interval. 1 They modeled three primary screening strategies, (1) primary cytology, (2) co-testing with cytology and HPV and (3) HPV testing alone. Co-testing was the most sensitive followed by primary HPV and primary cytology. The positive predictive value was highest for primary HPV testing (12 %), followed by co-testing (10.3 %) and primary cytology (9.6 %). The negative predictive value was comparable for the three testing strategies. Primary HPV testing detected more cases than cytology alone. Co-testing detected more cases, at a higher cost. The authors conclude that primary HPV testing is more effective and less expensive than primary cytology and is a cost-effective alternative to co-testing.
Should this study change our approach to cervical cancer screening? An important caveat to consider is that Bcosteffectiveness^cannot be shown unless the intervention is actually shown to be effective. Although there is some evidence to support primary HPV testing for cervical cancer screening, the evidence is limited. Limitations of the HPValone strategy are the reliance on CIN3 plus as the main outcome rather than cervical cancer mortality and on the relatively short follow-up of the primary HPV screening studies so far.
Although the American Society for Colposcopy and Cervical Cytology and the Society of Gynecologic Oncology suggest that HPV testing is an alternative screening option, this approach is not broadly endorsed.
2 USPSTF guidelines for women ≥30 years old are that either primary cytology or co-testing is a reasonable cervical cancer screening alternative. 3 The American College of Gynecology recommends primary cytology or co-testing, with co-testing as the Bpreferred screening strategy.^They state that Bprimary HPV testing every 3 years can be considered for women ≥25,ŵ hile acknowledging that the options of cytology alone or co-testing Bremain the options specifically recommended in most major society guidelines.^4 In conclusion, although primary HPV testing is not broadly endorsed by major society guidelines, if it is performed, it appears to be a cost-effective alternative to other more established screening strategies.
